Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia

Received 16 January 2008; accepted 27 February 2008.

Abstract

Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment of many patients with acute myeloid leukemia (AML). Despite extensive study, the appropriate role and timing of allogeneic and autologous transplantation in AML are poorly defined. This review critically analyzes the extensive literature, focusing on the recent advances, and provides practical recommendations for the use of HSCT in AML.

Key Words: Acute myeloid leukemia, Hematopoietic stem cell transplantation, Bone marrow transplantation, Reduced intensity, Acute leukemia, Graft-versus-leukemia effect

1 Division of Hematology & Oncology, Arthur G. James Cancer Hospital, Ohio State University, Columbus, Ohio

2 Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio

Correspondence and reprint requests: Edward A. Copelan, MD, Cleveland Clinic Foundation, Taussig Cancer Center, 9500 Euclid Avenue, R35, Cleveland, OH 44195

PII: S1083-8791(08)00108-0

doi:10.1016/j.bbmt.2008.02.019

12 of 18